Stockreport

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Demen...

Coya Therapeutics, Inc.  (COYA) 
PDF Five of the 8 planned FTD subjects have been enrolled to date; Results of study will inform Coya's randomized, double-blinded Phase 2 trial of COYA 302 in patients wi [Read more]